Kelly WK - Search Results

1

Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.

Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kelly WK, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS. Apolo AB, et al. Among authors: kelly wk. Urol Oncol. 2014 Jul;32(5):637-44. doi: 10.1016/j.urolonc.2013.12.012. Epub 2014 May 16. Urol Oncol. 2014. PMID: 24840869 Free PMC article.

2

Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies.

Halabi S, Vogelzang NJ, Ou SS, Kelly WK, Small EJ. Halabi S, et al. Among authors: kelly wk. J Urol. 2006 Jul;176(1):81-6. doi: 10.1016/S0022-5347(06)00566-0. J Urol. 2006. PMID: 16753374

3

New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?

Hoffman-Censits J, Lombardo K, McConkey D, Hahn NM, Bashir B, Kelly WK, Johnson B, Matoso A. Hoffman-Censits J, et al. Among authors: kelly wk. Urol Oncol. 2021 Oct;39(10):619-622. doi: 10.1016/j.urolonc.2021.05.013. Epub 2021 Jun 18. Urol Oncol. 2021. PMID: 34148797

4

Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.

Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, Wheeler MA, Kelly WK, Tew GN, Saltzman WM, Weiss RM. Martin DT, et al. Among authors: kelly wk. Nanomedicine. 2013 Nov;9(8):1124-34. doi: 10.1016/j.nano.2013.05.017. Epub 2013 Jun 11. Nanomedicine. 2013. PMID: 23764660 Free PMC article.

5

STEAP1 as a potential target for new therapies in prostate cancer.

Kelly WK. Kelly WK. Clin Adv Hematol Oncol. 2024 Jun;22(5):243-244. Clin Adv Hematol Oncol. 2024. PMID: 38805316 Review. No abstract available.

6

The development of differentiation agents for the treatment of prostate cancer.

Galsky M, Kelly WK. Galsky M, et al. Among authors: kelly wk. Semin Oncol. 2003 Oct;30(5):689-97. doi: 10.1016/s0093-7754(03)00355-5. Semin Oncol. 2003. PMID: 14571416 Review.

7

Epothilones: tubulin polymerization as a novel target for prostate cancer therapy.

Lee JJ, Kelly WK. Lee JJ, et al. Among authors: kelly wk. Nat Clin Pract Oncol. 2009 Feb;6(2):85-92. doi: 10.1038/ncponc1281. Epub 2008 Dec 2. Nat Clin Pract Oncol. 2009. PMID: 19048010 Review.

8

Screening for prostate cancer: the current evidence and guidelines controversy.

Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, Dicker A, Wender R. Gomella LG, et al. Among authors: kelly wk. Can J Urol. 2011 Oct;18(5):5875-83. Can J Urol. 2011. PMID: 22018148 Free article. Review.

9

Targeting epigenetics for the treatment of prostate cancer: recent progress and future directions.

Lin J, Wang C, Kelly WK. Lin J, et al. Among authors: kelly wk. Semin Oncol. 2013 Jun;40(3):393-401. doi: 10.1053/j.seminoncol.2013.04.010. Semin Oncol. 2013. PMID: 23806502

10

Practical guide to the use of enzalutamide.

Hoffman-Censits J, Kelly WK. Hoffman-Censits J, et al. Among authors: kelly wk. Can J Urol. 2014 Apr;21(2 Supp 1):64-9. Can J Urol. 2014. PMID: 24775726 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

231 results

Search Page

Filters